A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma

TAKESHI YAMADA\textsuperscript{1,2}, MANO HORINAKA\textsuperscript{1}, MASAHIDE SHINNOH\textsuperscript{1,2}, TAKASHI YOSHIOKA\textsuperscript{1,3}, TSUNEHARU MIKI\textsuperscript{2} and TOSHIYUKI SAKAI\textsuperscript{1}

Departments of \textsuperscript{1}Molecular-Targeting Cancer Prevention, \textsuperscript{2}Urology and \textsuperscript{3}Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Received April 22, 2013; Accepted June 10, 2013

DOI: 10.3892/ijo.2013.2042

Abstract. Renal cell carcinoma (RCC) is resistant to traditional cancer therapies such as radiation therapy and chemotherapy. The use of targeted therapies has improved the clinical outcomes of patients with metastatic RCC. However, most patients acquire resistance against targeted therapies over time. We report that the combination of the novel histone deacetylase (HDAC) inhibitor OBP-801, also known as YM753 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 synergistically inhibits cell growth and induces apoptosis in RCC cells. This combination activated caspase-3, -8 and -9 and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the treatment with OBP-801 and LY294002. Moreover, the combined treatment induced intracellular reactive oxygen species (ROS) and the radical scavenger N-acetyl-L-cysteine (NAC) blocked the intracellular ROS and apoptosis induced by OBP-801 and LY294002. The co-treatment with OBP-801 and LY294002 markedly decreased survivin and the X-linked inhibitor of apoptosis protein (XIAP) protein levels, but Bcl-2 family members were not altered by the OBP-801/LY294002 co-treatment. These alterations were restored by NAC treatment. The transient transfection of survivin and XIAP reduced the apoptotic response to the OBP-801/LY294002 co-treatment. Additionally, OBP-801 was significantly more effective than SAHA, another HDAC inhibitor, in the combination with LY294002 against 786-O cells. Taken together, these results strongly suggest the combination of OBP-801 and LY294002 to be a promising treatment for RCC.

Introduction

Renal cell carcinoma (RCC), the most common malignant tumor of the kidney, accounts for 2-3% of adult malignancies. It causes about 102,000 deaths worldwide per year (1-3). Several molecular-targeting agents for RCC have been developed; the multi-tyrosine kinase inhibitors sorafenib and sunitinib, and the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus. One of the major activities of these agents against RCC has been believed to be their angiogenesis-inhibitory effect. Despite the success of these agents, drug resistance is an urgent problem, which underscores the need for new treatment strategies to improve clinical outcomes (4-6).

Histone deacetylase (HDAC) inhibitors are promising anticancer agents that induce growth arrest, differentiation and apoptosis in various types of tumor cell lines (7,8). We identified OBP-801, also known as YM753, as a novel HDAC inhibitor with attractive pharmacodynamic and pharmacokinetic properties by screening for a p21\textsuperscript{WAF1/Cip1}-inducing agent (9). OBP-801 was exerted most potent HDAC-inhibitory activity tested; it was about 50 times more effective than SAHA, the most clinically used HDAC inhibitor (9).

Phosphatidylinositol 3-kinase (PI3K) is a major signaling component downstream of growth factor receptor tyrosine kinases (10). Phosphatidylinositol 3,4,5-trisphosphate (PIP3) generated by PI3K at the cell membrane is a lipid second messenger and contributes to the activation of the serine-threonine protein kinase Akt (10,11). The PI3K-Akt signaling pathway is a key regulator of cell growth through many downstream targets. Therefore, the PI3K inhibitor LY294002 can inhibit cell growth and cause apoptosis also in RCC cells (11-15).
Previous reports showed that co-treatment with an HDAC inhibitor and a PI3K inhibitor was effective against ovarian cancer, cervical cancer, non-small cell lung cancer, colon cancer, chronic myeloid leukemia and cutaneous T-cell lymphoma by downregulating XIAP and Mcl-1 (16-21). The PI3K-Akt pathway is well known to be upregulated in most RCC, but the combination of a PI3K inhibitor and an HDAC inhibitor has not been examined in RCC cells. Therefore, we examined if this combination was effective on RCC and found that the co-treatment of the PI3K inhibitor LY294002 with the novel HDAC inhibitor OBP-801 drastically induced apoptosis through the strong suppression of survivin as well as XIAP via ROS production. This is the first report that the downregulation of survivin at least partially contributes to the synergistic effect of the HDAC inhibitor with the PI3K inhibitor.

Materials and methods

Reagents. OBP-801 (Oncolys BioPharma, Tokyo, Japan), LY294002 (Cell Signaling Technology, Beverly, MA, USA), SAHA (Biomol Research Laboratories, Plymouth Meeting, PA, USA) and zVAD-fmk (R&D Systems, Minneapolis, MN, USA) were dissolved in DMSO. N-acetyl-L-cysteine (NAC) was purchased from Nacalai Tesque (Kyoto, Japan).

Cell culture. Human renal cancer 786-O and ACHN cell lines were maintained in RPMI-1640 and DMEM, respectively. Culture media were supplemented with 10% FBS, glutamine (2 mM for RPMI-1640 and 4 mM for DMEM), 100 U/ml penicillin and 100 µg/ml streptomycin. Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO₂.

Cell viability assay. The number of viable cells was determined using a Cell Counting kit-8 assay according to the manufacturer’s instructions (Dojindo Laboratories, Kumamoto, Japan). After the incubation of cells for 72 h with the indicated concentrations of OBP-801 or LY294002, the kit reagent WST-8 was added to the medium and cells were incubated for a further 4 h. The absorbance of samples (450 nm) was determined using a scanning multiwell spectrophotometer (DS Pharma Biomedical, Osaka, Japan).

Detection of apoptosis. DNA fragmentation was quantified by the percentage of hypodiploid DNA (sub-G1). Cells were harvested from culture dishes, washed with PBS and treated with PBS containing 0.1% Triton X-100. Cells were then treated with RNase A (Sigma, St. Louis, MO, USA) and the nuclei were stained with propidium iodide (Sigma). DNA content was measured using a FACSCalibur flow cytometer and CellQuest software (Becton-Dickinson, Franklin Lakes, NJ, USA). For each experiment, 10,000 events were analyzed.

Western blot analysis. Western blot analysis was carried out as described previously (22). The following antibodies were purchased from the indicated sources: rabbit polyclonal antibodies for anti-survivin (R&D Systems), anti-caspase-3, -8, -9 (Cell Signaling Technology, anti-Bcl-2 (Abcam, Cambridge, UK), anti-BAX and anti-Bcl-xL (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse monoclonal antibodies for anti-XIAP (R&D Systems), anti-caspase, and anti-β-actin (Sigma) were used as primary antibodies. The signal was detected using a Chemilumi-one chemiluminescent kit (Nacalai Tesque).

Plasmid DNA transfection. The pCMV6-XL5 control, pCMV6-XL5/survivin and pCMV6-XL5/XIAP plasmid constructs were purchased from OriGene Technologies (Rockville, MD, USA). 786-O cells were seeded at 1x10⁵ cells per well in 6-well plates without antibiotics. After 24 h, plasmid DNA (4 µg) was transfected into cells using HilyMax transfection reagent (Dojindo Laboratories) according to the manufacturer's instructions. Four hours after the transfection, the medium was replaced with fresh medium and cells were treated with or without OBP-801/LY294002 for 48 h and then harvested.

Measurement of intercellular ROS. For the measurement of ROS production, cells were treated with 10 µM 5- and 6-chloromethyl-2,7-dichlorodihydrofluorescein diacetate acetyl ester (CM-H₂DCFDA) (Molecular Probes, Carlsbad, CA, USA). After 30 min of incubation with CM-H₂DCFDA, fluorescence was monitored in the FL-1 channel by FACSCalibur using the CellQuest software.

Combination index. We calculated the combination index for OBP-801 and LY294002 using CalcuSyn 2.0 software (Biosoft, Great Shelford, UK).

Statistical analysis. Data were expressed as mean ± SD of three determinations. Statistical analysis was performed using the Student's t-test. Samples were considered significantly different at P<0.05.

Results

The combination of OBP-801 and LY294002 synergistically inhibits cell growth and induces apoptosis in RCC 786-O cells. To examine the growth-inhibitory effect of OBP-801 or LY294002 alone, we assessed the viable cell number of 786-O cells after 72 h of treatment with the indicated concentrations of agents. Each agent was effective against cell growth in a dose-dependent manner in 786-O and ACHN cells (Fig. 1A). Interestingly, co-treatment with low-dose OBP-801 and LY294002 synergistically inhibited cell growth less than that of cells treated with either single agent in 786-O and ACHN cells (Fig. 1B). Moreover, the combination index (CI) values for OBP-801 and LY294002 were <1.0, indicating a synergistic effect for the inhibition of cell growth (Fig. 1C). To clarify the mechanisms of synergistic inhibitory effects on cell growth by the combination of OBP-801 and LY294002, we investigated the effects of the combination on apoptosis by measuring the sub-G1 population. OBP-801 or LY294002 alone weakly induced apoptosis, but the co-treatment with OBP-801 and LY294002 more remarkably induced apoptosis in 786-O cells (Fig. 1D). These results indicate that the combination of OBP-801 and LY294002 synergistically inhibits cell growth and induces apoptosis in 786-O cells.
whether the apoptosis induced by the combination of OBP-801 and LY294002 depends on caspases using the pan-caspase inhibitor zVAD-fmk. Treatment with zVAD-fmk effectively inhibited the apoptosis induced by the co-treatment with OBP-801 and LY294002 (Fig. 2A). Additionally, we performed western blotting of caspase-3, -8 and -9. Treatment with OBP-801 or LY294002 alone did not induce the cleavage of caspases, but the co-treatment with OBP-801 and LY294002 induced caspase cleavage (Fig. 2B). These results suggest that the combination of OBP-801 and LY294002 induces apoptosis dependent on caspase in 786-O cells.
ROS are responsible for the apoptosis induced by the combination of OBP-801 and LY294002 in 786-O cells. It has been reported that the apoptosis induced by the combination of a HDAC inhibitor and a PI3K inhibitor is associated with the intracellular accumulation of ROS (19). We also found that the co-treatment with OBP-801 and LY294002 induced intracellular ROS and the free radical scavenger, NAC, blocked the intracellular ROS induced by the co-treatment in 786-O cells (Fig. 3A). Moreover, NAC blocked OBP-801/LY294002-induced apoptosis in 786-O cells (Fig. 3B). These results suggest that the apoptosis induced by the combination of OBP-801 and LY294002 is dependent on ROS production.

The combination of OBP-801 and LY294002 decreases protein levels of survivin and XIAP through ROS generation in 786-O cells. To clarify the molecular mechanism of the apoptosis induced by the combination of OBP-801 and LY294002, we performed western blot analysis. As shown in Fig. 4A, the expression of anti-apoptotic molecules such as survivin and XIAP with the co-treatment of OBP-801 and LY294002 was significantly lower than with either single agent. Bcl-2, BAX, and Bcl-xL protein levels were not affected by the co-treatment with OBP-801 and LY294002 (Fig. 4B). Next, we investigated further whether ROS generation could cause the downregulation of survivin and XIAP. As shown in Fig. 4C, the downregulation of survivin and XIAP was restored by NAC treatment. These results suggest that the downregulation of survivin and XIAP induced by the combination of OBP-801 and LY294002 is ROS-dependent.

Downregulation of survivin and XIAP is involved in the apoptosis induced by the combination of OBP-801 and LY294002. We examined whether overexpression of survivin and XIAP contributed to the resistance to the co-treatment with OBP-801 and LY294002. The effects of the overexpression of survivin and XIAP were confirmed by western blotting (Fig. 5A). As shown in Fig. 5B, the overexpression of survivin or XIAP partially suppressed OBP-801/LY294002-induced apoptosis.
whereas the co-expression of survivin and XIAP considerably suppressed it. These results suggest that the combination of OBP-801 and LY294002 causes apoptosis at least partially through the downregulation of survivin and XIAP in 786-O cells.

In the combination with LY294002, OBP-801 more strongly induces apoptosis than SAHA in 786-O cells. Suberoylanilide hydroxamic acid (SAHA) is the most clinically used HDAC inhibitor (23). To compare OBP-801 and SAHA in combination with LY294002, we analyzed sub-G1 by flow cytometry. As shown in Fig. 6A, OBP-801 or SAHA alone almost equally induced apoptosis, but co-treatment with OBP-801 and LY294002 more remarkably induced apoptosis than that with SAHA and LY294002 in 786-O cells. These results indicate that OBP-801 is significantly more effective than SAHA in the combination with LY294002 in 786-O cells.

Discussion

HDAC inhibitors have been reported to have potent anticancer activity in various cancer types, but their role as monotherapies appears to be limited. Considering the pleiotropic effects of HDAC inhibitors against malignant tumors, their true therapeutic potential most likely lies in combinations with other anticancer drugs (24). Recent clinical trials have indicated that HDAC inhibitors enhance the antitumor activities of several conventional chemotherapeutic and molecular-target drugs (25-27). Additionally, a previous study showed that HDACs were highly expressed in RCC, suggesting that HDAC inhibitors may be effective on RCC (28).

Recently, the mTOR inhibitors everolimus and temsirolimus have been clinically used as a treatment against RCC, but are not curative. mTOR is known to inhibit the insulin receptor substrate-1 (IRS-1), which plays a key role in transmitting signals from insulin-like growth factor-I (IGF-I) receptors to the PI3K-Akt pathway. Therefore, mTOR inhibitors reactivate the PI3K-Akt pathway resulting in resistance (29). We then selected a PI3K inhibitor as a combination-therapeutic partner of the HDAC inhibitor.

We showed that the OBP-801/LY294002 co-treatment specifically downregulated survivin and XIAP proteins in 786-O cells (Fig. 4A). Furthermore, the overexpression of survivin and/or XIAP reduced the apoptotic response to

Figure 4. OBP-801 and LY294002 downregulate the expression of survivin and XIAP. (A) Western blotting of IAP family members (survivin and XIAP). 786-O cells were treated with 4 nM OBP-801 and/or 5 µM LY294002 for 48 h. β-actin is shown as a loading control. (B) Western blotting of Bcl-2 family members (Bcl-2, BAX and Bcl-xL). 786-O cells were treated as shown in (A). β-actin is shown as a loading control. (C) Western blotting of survivin and XIAP. 786-O cells were treated with 4 nM OBP-801 and/or 5 µM LY294002 with or without 5 mM NAC for 48 or 72 h. β-actin is shown as a loading control.

Figure 5. Survivin and XIAP are involved in OBP-801/LY294002-induced apoptosis. (A) 786-O cells were transfected with plasmids as indicated. Twenty-four hours after the transfection, cells were treated with or without 4 nM OBP-801 and 5 µM LY294002 for 48 h and were then harvested, followed by western blotting of survivin and XIAP. β-actin is shown as a loading control. (B) 786-O cells were transfected as described in (A). Twenty-four hours after the transfection, cells were treated with or without 4 nM OBP-801 and 5 µM LY294002 for 48 h. The sub-G1 population was analyzed by flow cytometry. Columns, means of triplicate data; bars, SD; *P<0.05.
survivin and XIAP is upregulated by nuclear factor-κB (NF-κB) (33-35) and that NF-κB activity is suppressed by ROS (36). Therefore, the downregulation of survivin and XIAP in this study might be caused by the ROS-dependent suppression of NF-κB activity.

A recent report has shown that the combination of OBP-801 and LY294002 synergistically induces apoptosis through the upregulation of Bim with accumulation of ROS in human endometrial carcinoma HEC-1A cells (37). However, in our experiments, OBP-801/LY294002 co-treatment did not induce Bim expression in RCC 786-O cells (data not shown). These results suggest that there are different mechanisms of apoptosis induced by the OBP-801/LY294002 co-treatment between the two cell lines.

Our results showed that OBP-801 more markedly induced apoptosis than SAHA, the most clinically used HDAC inhibitor, when combined with LY294002 (Fig. 6A). Interestingly, the co-treatment with SAHA and LY294002 did not decrease the expression of survivin and XIAP proteins (data not shown). Therefore, the mechanism for differences in the efficacy of both agents may be attributed to the downregulation of survivin and XIAP.

In conclusion, we demonstrated that the novel HDAC inhibitor OBP-801 and the PI3K inhibitor LY294002 synergistically induced apoptosis by ROS-dependent downregulation of survivin and XIAP in 786-O cells (Fig. 6B). These observations raise the possibility that the combination of OBP-801 and PI3K inhibitors may be promising for the treatment of RCC.

Acknowledgements

We thank Drs Y. Sowa, S. Yogosawa, M. Tomosugi and M. Koyama for their useful discussion. This study was partly supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology.

References


